Tracy Morgan's The View Confirmation: Ozempic, Diabetes, and the 40-Pound Loss

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 12 sources cited · Author: FormBlends Editorial

Key Takeaways

• Tracy Morgan confirmed Ozempic use on The View in April 2024, casually and on live daytime television
• His use is FDA-indicated because he has type 2 diabetes; Ozempic is approved for that indication
• He reported approximately 40 pounds of weight loss, which he attributed to medication plus a four-day-per-week workout routine
• His confirmation included candid references to side effects (gastrointestinal effects, reduced appetite), delivered comedically
• His disclosure was notable for its on-label legitimacy: he was using the medication for what it was approved for, not off-label cosmetic weight loss

Direct answer

Yes, Tracy Morgan has confirmed Ozempic use. He made the disclosure on a live April 2024 appearance on The View. He has type 2 diabetes, which makes his Ozempic prescription FDA-indicated rather than off-label. He reported losing approximately 40 pounds, combining the medication with a four-day-per-week workout routine. His statement was casual, comedic, and unscripted, which made it one of the more disarming celebrity GLP-1 confirmations of the 2024 disclosure wave.

Table of contents

1. What Tracy Morgan actually said
2. The April 2024 View appearance
3. His type 2 diabetes context
4. Why his case is FDA-indicated, not off-label
5. The 40-pound loss and his workout routine
6. Side effects he discussed openly
7. How his confirmation fit the 2024 disclosure wave
8. The contrary view: does FDA-indicated use change the cultural reading?
9. Decision framework
10. FAQ
11. Sources

What Tracy Morgan actually said

Morgan's confirmation on The View was direct. The exchange unfolded roughly as follows:

The hosts had been discussing his recent appearance and his weight loss. Morgan, with his characteristic comedic delivery, said something to the effect of: "I work out four days a week, and the Ozempic. They're not paying me to say that. I take an Ozempic shot every week."

He went on to describe the medication's effects:

• Reduced appetite ("I could eat one cracker and feel like I just had a turkey dinner")
• Frequent bathroom visits, delivered as a punchline
• Sustained weight loss as a function of consistent use plus the workout routine

The confirmation was casual, unscripted, and treated comedically. He did not stage it as a major revelation or use it as a platform for advocacy. The framing was matter-of-fact: he uses the medication, here is what it does, moving on.

The April 2024 View appearance

The View, the long-running ABC daytime talk show, has produced multiple celebrity GLP-1 confirmations. Whoopi Goldberg confirmed Mounjaro on the show; Tracy Morgan confirmed Ozempic; other guests have discussed the medications in various ways.

Morgan's appearance in April 2024 was during a press cycle for his Paramount+ comedy special and other projects. The Ozempic discussion was not the planned topic; it emerged from a discussion of his appearance and his recent fitness focus.

The format mattered. The View is live daytime television with a broad audience. Disclosures on the show reach viewers who do not engage with podcasts or longer-form interviews. The casualness of the medium matched the casualness of Morgan's delivery, producing a confirmation that felt unrehearsed and credible.

His type 2 diabetes context

Tracy Morgan has discussed his type 2 diabetes for many years. The diagnosis predates Ozempic's FDA approval (December 2017). His diabetes management has been part of his public health discussions across his career.

Key context:

• He was diagnosed with type 2 diabetes well before his June 2014 traffic accident
• His health and recovery have been a public topic since the accident
• He has discussed weight, diet, and management openly
• His diabetes treatment has likely included multiple medications over the years

Ozempic is FDA-approved for type 2 diabetes. Morgan's use is FDA-indicated. The weight loss is a documented side effect of the medication's mechanism (delayed gastric emptying, reduced glucagon, increased satiety signaling), which is exactly why semaglutide was subsequently approved at higher doses as Wegovy for obesity.

Why his case is FDA-indicated, not off-label

The distinction matters culturally and clinically. Many celebrity Ozempic confirmations involve off-label use: the celebrity takes Ozempic for weight loss despite not having diabetes. Morgan's case is different.

Morgan's case illustrates the original purpose of Ozempic. Patients with type 2 diabetes benefit from the medication's glucose-control effect; the appetite-suppression and weight-loss effects are valuable secondary benefits. This is the medication being used as designed.

The 40-pound loss and his workout routine

Morgan reported approximately 40 pounds of weight loss. The pattern he described:

• Four days per week of workouts
• Weekly Ozempic injection
• Reduced food intake as a consequence of the medication's appetite effect
• Sustained pattern over months

For a patient with type 2 diabetes and his reported pre-treatment weight, 40 pounds is consistent with what clinical literature describes. The 2017 SUSTAIN trial series for Ozempic in diabetes populations found weight loss of approximately 3-6% on average at the 1 mg dose. Higher-dose use (as in obesity-indication Wegovy) produces larger losses.

Forty pounds is at the upper end of what is typically observed in diabetes-population Ozempic trials. The combination with consistent exercise plausibly accounts for the higher result. The medication-plus-exercise pairing is the recommended approach in major diabetes-management guidelines.

Side effects he discussed openly

Morgan's side-effect references during the disclosure:

• Increased bathroom frequency (consistent with the gastrointestinal effects of GLP-1 medications; nausea and diarrhea are common, particularly during titration)
• Reduced appetite to a degree that surprised him (he described feeling full from very small amounts of food)
• The "having to be near a toilet" comment was comedic but referenced a real medication characteristic

The candor about side effects strengthened the credibility of the confirmation. A fabricated story would more likely emphasize positives. Morgan's account included the friction (GI symptoms, dietary adjustment), which is what real patients report.

FormBlends clinical observation: patients on GLP-1 medications typically describe similar side-effect patterns to what Morgan referenced. The honesty about the GI effects is consistent with actual patient experience rather than an idealized narrative.

How his confirmation fit the 2024 disclosure wave

The 2024 disclosure wave included:

Morgan's confirmation was distinct from Oprah's. Oprah framed her disclosure as a public-health intervention, with the weight-stigma framing of her ABC special. Morgan's was comedic, casual, and clinically straightforward (he has diabetes; the medication is approved for that).

The variety of disclosure styles (public-health-framed, comedic-casual, commercial-partnership, talk-show-spontaneous) helped normalize GLP-1 disclosure across multiple registers. Morgan's contribution was the comedic-casual register, which reached audiences that the more produced disclosures might not have.

The contrary view: does FDA-indicated use change the cultural reading?

The strongest argument that Morgan's case is different in kind:

Argument 1: FDA-indicated use is not the same conversation.

The cultural anxiety around celebrity Ozempic centers on off-label cosmetic use by people who do not need the medication. Morgan does need it. His use is for the indication the medication was approved for. The cultural critique of "celebrity Ozempic" does not apply to him in the same way.

Argument 2: His example may mislead about the typical case.

Most celebrity Ozempic users do not have diabetes. Morgan's clear-cut FDA-indicated use is unrepresentative of the broader celebrity GLP-1 phenomenon. Audiences that take his disclosure as representative may miss the off-label problem that affects most other celebrity cases.

Argument 3: The weight-loss focus understates the diabetes context.

The cultural reading of Morgan's disclosure has emphasized the 40-pound loss. The clinical reading would emphasize the diabetes-management improvement (lower HbA1c, better glycemic control), which is the medical purpose of the medication. The framing as "celebrity weight loss" partially misrepresents what the medication is doing for him.

The counter: his transparency about all elements (medication, diet, exercise, side effects, diabetes status) made his disclosure educational. Whether the broader culture took the right lessons is a separate question from whether his disclosure was useful in its own right.

Decision framework

If you have type 2 diabetes and are considering Ozempic:

• Ozempic is FDA-approved for your indication and is widely used for glycemic control
• Weight loss is a documented secondary benefit
• Insurance coverage is typically more accessible than for off-label cosmetic use
• Discuss dose titration, side effects, and contraindications with your prescriber

If you do not have diabetes but are considering GLP-1 medication for weight loss:

• Wegovy (semaglutide 2.4 mg) is the FDA-approved obesity-indication formulation
• Eligibility is BMI 30+, or BMI 27+ with comorbidities
• Off-label Ozempic use is legal but diverts supply from diabetes patients
• Morgan's example is not representative of your situation; your case is closer to other celebrity examples

If you are evaluating his case as a model:

• The medication-plus-exercise pairing is well-supported by clinical literature
• The 40-pound loss is at the upper range for diabetes-indication outcomes but is plausible
• The candor about side effects is a useful realism check

FAQ

Did Tracy Morgan confirm he uses Ozempic? Yes. Tracy Morgan confirmed Ozempic use during an April 2024 appearance on The View. He stated openly that he was taking the medication, joked about its appetite-suppressing effects, and was matter-of-fact about it. He also has type 2 diabetes, which means Ozempic is an FDA-approved use case for him.

What did Tracy Morgan say about Ozempic on The View? Morgan said something to the effect of: "I work out four days a week, and the Ozempic. They're not paying me to say that. I take an Ozempic shot every week." He joked that the medication made him have to be at the toilet more often and that he could only eat half of what he used to.

Does Tracy Morgan have type 2 diabetes? Yes. Tracy Morgan has been public about his type 2 diabetes diagnosis for many years. He was diagnosed before his 2014 traffic accident, and his diabetes management has been a recurring topic in his public health discussions. Ozempic is FDA-approved for type 2 diabetes, which makes his use FDA-indicated.

How much weight did Tracy Morgan lose on Ozempic? Morgan has described losing approximately 40 pounds. He has attributed the loss to a combination of Ozempic and a workout routine, emphasizing both elements as contributors rather than crediting medication alone.

Is Tracy Morgan's Ozempic use FDA-approved? Yes. Because Morgan has type 2 diabetes, his use of Ozempic falls within the FDA-approved indication for the medication. Ozempic was approved for type 2 diabetes in December 2017. This is the on-label use; weight management is a beneficial side effect of his diabetes treatment rather than an off-label cosmetic application.

Why is Tracy Morgan's confirmation important? His confirmation was notable because it was unusually casual and unscripted. It happened on a live daytime talk show, was treated comedically by Morgan himself, and showed an FDA-indicated patient discussing the medication openly. The combination of clinical legitimacy plus humor helped normalize the conversation around GLP-1 medications in 2024.

What dose of Ozempic does Tracy Morgan take? He has not specified the dose. Ozempic is dosed weekly, titrated from 0.25 mg up to 2.0 mg depending on tolerance and clinical response. Most patients with type 2 diabetes are maintained at 1.0 mg or 2.0 mg weekly after initial titration.

Did Tracy Morgan describe side effects? Yes, mostly comedically. He referenced needing to be near a toilet more often, which is consistent with the gastrointestinal side effects of GLP-1 medications. He also described reduced appetite ("I can only eat half"), which is the appetite-suppressing effect that drives weight loss.

Should I take Ozempic for weight loss because Tracy Morgan does? Only if you have type 2 diabetes (Morgan's situation) or, separately, only if you meet FDA criteria for Wegovy (BMI 30+, or BMI 27+ with comorbidities). His example does not justify off-label cosmetic use for people outside these criteria.

Could Morgan's weight loss have come from exercise alone? Forty pounds is at the upper end of what consistent exercise alone produces, particularly for someone with type 2 diabetes (which can complicate weight regulation). The combination of medication and exercise is the more plausible explanation, which is what he himself described.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM. 2021. (STEP 1)
2. Sorli C et al. Efficacy and Safety of Once-Weekly Semaglutide vs Placebo in Type 2 Diabetes (SUSTAIN 1). Lancet Diabetes Endocrinol. 2017.
3. FDA Drug Approvals Database. Ozempic approval, December 5, 2017.
4. FDA Drug Approvals Database. Wegovy approval, June 4, 2021.
5. American Diabetes Association. Standards of Care in Diabetes 2024.
6. The View. Tracy Morgan appearance, April 2024.
7. The View. Whoopi Goldberg Mounjaro disclosure, 2024.
8. Garvey WT et al. Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine Practice. 2016.
9. Davies MJ et al. Gastrointestinal Adverse Events with GLP-1 Receptor Agonists. Diabetes Care. 2023.
10. American Association of Clinical Endocrinologists. Clinical Practice Guidelines for Obesity Management. 2022.
11. ADA. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Medical Care in Diabetes. 2024.
12. Pearl RL et al. Weight Bias and Stigma: Public Health Implications. Obesity. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends connects eligible patients with U.S.-licensed providers and pharmacies. We do not prescribe medication. All clinical decisions are made by independent licensed providers. FormBlends does not treat diabetes; patients with diabetes should work with a diabetes-care provider.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved products. They are produced by state-licensed 503A compounding pharmacies for individual prescriptions. Compounded products are not equivalent to brand Ozempic, Wegovy, Mounjaro, or Zepbound.

Results Disclaimer. Tracy Morgan's reported 40-pound weight loss reflects his individual case, including his combination of medication, four-day-per-week exercise, and ongoing diabetes management. Individual outcomes vary substantially based on starting weight, comorbidities, adherence, and other factors.

Trademark Notice. Ozempic and Wegovy are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly. The View is a registered trademark of ABC / Disney. Paramount+ is a registered trademark of Paramount. FormBlends is not affiliated with, endorsed by, or sponsored by Tracy Morgan, The View, ABC, Paramount, Novo Nordisk, Eli Lilly, or any other party referenced in this article.